KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aquestive Therapeutics (AQST) EBIT (2017 - 2025)

Historic EBIT for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to -$11.5 million.

  • Aquestive Therapeutics' EBIT fell 3846.8% to -$11.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$55.8 million, marking a year-over-year decrease of 16437.47%. This contributed to the annual value of -$30.8 million for FY2024, which is 10375.45% down from last year.
  • Aquestive Therapeutics' EBIT amounted to -$11.5 million in Q3 2025, which was down 3846.8% from -$11.4 million recorded in Q2 2025.
  • In the past 5 years, Aquestive Therapeutics' EBIT registered a high of $55000.0 during Q2 2024, and its lowest value of -$19.4 million during Q1 2025.
  • In the last 5 years, Aquestive Therapeutics' EBIT had a median value of -$8.9 million in 2022 and averaged -$8.7 million.
  • As far as peak fluctuations go, Aquestive Therapeutics' EBIT surged by 10130.67% in 2024, and later crashed by 2076909.09% in 2025.
  • Over the past 5 years, Aquestive Therapeutics' EBIT (Quarter) stood at -$11.7 million in 2021, then rose by 8.19% to -$10.7 million in 2022, then skyrocketed by 63.49% to -$3.9 million in 2023, then tumbled by 247.2% to -$13.6 million in 2024, then grew by 15.47% to -$11.5 million in 2025.
  • Its EBIT stands at -$11.5 million for Q3 2025, versus -$11.4 million for Q2 2025 and -$19.4 million for Q1 2025.